William Meador
Neurology · Birmingham, ALNPI 1861629230
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Biogen at 49.7% of the total. That places this record below the midpoint for neurology clinicians in AL, where the typical reported total is $2,219.
Across 4 payments — averaging $82.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$164
- Roche Products Limited$126
- Genentech, Inc.$40
Across 59 payments — averaging $6570.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$328K
- AstraZeneca$59K
- Sanofi$1K
What the payments were for
- Consulting fees$15045%
- Food & beverage$14143%
- Education$4012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 2 | $164 |
| Roche Products Limited | 1 | $126 |
| Genentech, Inc. | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYSABRI$150
How this compares
$330 in reported general payments places this provider in the 25th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 125 | $1,090,225 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $912,320 |
| EnspryngSatralizumab-Mwge | 42 | $701,620 |
| OcrevusOcrelizumab | 17 | $644,985 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 37 | $460,669 |
| MayzentSiponimod | 44 | $396,890 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $235,406 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 19 | $191,818 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $134,915 |
| TecfideraDimethyl Fumarate | 13 | $109,768 |
| FingolimodFingolimod Hcl | 39 | $99,127 |
| CopaxoneGlatiramer Acetate | 13 | $71,332 |
| Glatiramer Acetate | 19 | $61,141 |
| Dimethyl Fumarate | 40 | $33,093 |
| Emgality PenGalcanezumab-Gnlm | 30 | $22,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Ocrevus | $40 | $644,98517 claims |
| BiogenTecfidera | $164 | $109,76813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 255 neurology providers in Alabama.
Other neurology in Birmingham
- Diane CounceBirmingham$895K
- Emily RiserBirmingham$231K
- Wesley KingBirmingham$167K
- Jerzy SzaflarskiBirmingham$164K
- Victor SungBirmingham$138K
- Raymond FaughtBirmingham$99K
- David GeldmacherBirmingham$99K
- David StandaertBirmingham$82K
- Richard DiethelmBirmingham$65K
- Mina LobbousBirmingham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.